Novartis's Sandoz to Commercialize Multiple Sclerosis Treatment in Europe
2023年9月26日 - 3:03PM
Dow Jones News
By Mauro Orru
Novartis's generics-and-biosimilars division Sandoz was granted
marketing authorization from the European Commission to
commercialize and distribute Tyruko to treat relapsing forms of
multiple sclerosis in the bloc.
The company said Tuesday that Sandoz has the right to
commercialize and distribute Tyruko in markets where it is approved
through an exclusive agreement with Polpharma Biologics, which
makes the treatment. Polpharma Biologics will maintain
responsibilities for development of the medicine.
"Today's approval brings us one step closer to reducing the
burden of this disease for those living with multiple sclerosis in
Europe by making the life-enhancing treatments they need more
accessible," said Rebecca Guntern, President for Europe at
Sandoz.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
September 26, 2023 01:48 ET (05:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
過去 株価チャート
から 4 2024 まで 5 2024
Novartis (NYSE:NVS)
過去 株価チャート
から 5 2023 まで 5 2024
